Vyome vs Serina Therapeutics
HIND and SER side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How HIND and SER compare
Serina Therapeutics is the larger company, worth 3.1 times as much as Vyome ($35.8M against $11.4M).
Serina Therapeutics scores higher on the StockData Score (2 against 1 for Vyome), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | HIND | SER |
|---|---|---|
| Size and price | ||
| Market cap | $11.4M | $35.8M |
| Share price | $1.63 | $1.41 |
| Change, 1 year | −69.3% | −65.4% |
| Change, 5 years | −100.0% | −94.9% |
| Beta (5Y) | 1.56 | 0.35 |
| Employees | 18 | 16 |
| StockData Score | ||
| Total score | 1 | 2 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 1 (better) |
| Performance score | 0 | 0 |
| Health score | 1 | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 74.7× | – |
| P/B | – | 2.6× |
| FCF yield | – | −63.8% |
| Growth | ||
| Revenue growth (TTM) | −55.6% | – |
| Revenue growth, 5Y average | −51.0% | −18.5% (better) |
| Profitability | ||
| Gross margin | 50.4% | – |
| Operating margin | −2854% | – |
| Net margin | −2456% | – |
| Return on equity | −149% (better) | −312% |
| Financial health | ||
| Interest coverage | −229.3× | – |
| Current ratio | 3.68 | 4.62 (better) |
| Altman Z-score | −12.21 | −1.82 (better) |
| Piotroski F-score | 4 (better) | 3 |
| Dividends and buybacks | ||
| Buyback yield | −51.5% | – |
| Shareholder yield | −51.5% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 2.0% | 5.5% |
| Held by insiders | 6.8% | 49.7% |
| Insider net buying, 12 months | – | −$232K |
| Short interest, % of float | 0.28% | 0.37% |
Go deeper
- HIND stock overview
- HIND income statement
- HIND valuation and score
- SER stock overview
- SER income statement
- SER valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.